Endocrinology, Vol 136, 2635-2640, Copyright © 1995 by Endocrine Society

ARTICLES

Both of the beta-subunit carbohydrate residues of follicle-stimulating hormone determine the metabolic clearance rate and in vivo potency

LA Bishop, TV Nguyen and PR Schofield
Garvan Institute of Medical Research, St. Vincent's Hospital, Darlinghurst, Sydney, Australia.

FSH is a glycoprotein hormone required for the development and maturation of the ovarian follicle and for spermatogenesis. FSH is glycosylated at asparagine residues 52 and 78 on the alpha-subunit and residues 7 and 24 on the beta-subunit. In vitro, the carbohydrate residue at position alpha 52 is required for signal transduction. To define the contribution of the carbohydrate residues to FSH potency in vivo, we assessed the MCR and in vivo bioactivity of site-specifically deglycosylated recombinant human FSH variants. The removal of the beta- subunit carbohydrate residues significantly (P < 0.05) affected the MCR and resulted in significantly (P < 0.05) reduced in vivo bioactivity. For all recombinant human FSH variants, a strong correlation (r = 0.90; P < 0.01) was observed between MCR and in vivo potency, indicating that the circulatory half-life of the hormone appears to be the primary determinant of in vivo bioactivity. Although the beta-subunit carbohydrate residues have the greatest effect in determining FSH potency in vivo; the alpha 52 residue, important in vitro, has no effect on either MCR or in vivo potency. This study highlights the difficulties of translating in vitro results to whole animal physiology.

This article has been cited by other articles:

				A. Balen, P. Platteau, A. N. Andersen, P. Devroey, L. Helmgaard, J.-C. Arce, and for the Bravelle Ovulation Induction (BOI) Study G Highly purified FSH is as efficacious as recombinant FSH for ovulation induction in women with WHO Group II anovulatory infertility: a randomized controlled non-inferiority trial Hum. Reprod., July 1, 2007; 22(7): 1816 - 1823. [Abstract] [Full Text] [PDF]

				C.-H. Wong, D. D. Mruk, W. M. Lee, and C. Y. Cheng Targeted and reversible disruption of the blood-testis barrier by an FSH mutant-occludin peptide conjugate FASEB J, February 1, 2007; 21(2): 438 - 448. [Abstract] [Full Text] [PDF]

				A. Ulloa-Aguirre, C. Timossi, J. Barrios-de-Tomasi, A. Maldonado, and P. Nayudu Impact of Carbohydrate Heterogeneity in Function of Follicle-Stimulating Hormone: Studies Derived from in Vitro and in Vivo Models Biol Reprod, August 1, 2003; 69(2): 379 - 389. [Abstract] [Full Text] [PDF]

				W. J. Walton, V. T. Nguyen, V. Y. Butnev, V. Singh, W. T. Moore, and G. R. Bousfield Characterization of Human FSH Isoforms Reveals a Nonglycosylated {beta}-Subunit in Addition to the Conventional Glycosylated {beta}-Subunit J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3675 - 3685. [Abstract] [Full Text] [PDF]

				T. Zarinan, A. Olivares, D. Soderlund, J.P. Mendez, and A. Ulloa-Aguirre Changes in the biological:immunological ratio of basal and GnRH-releasable FSH during the follicular, pre-ovulatory and luteal phases of the human menstrual cycle Hum. Reprod., August 1, 2001; 16(8): 1611 - 1618. [Abstract] [Full Text] [PDF]

				M. Bergendah and J. D. Veldhuis Is there a physiological role for gonadotrophin oligosaccharide heterogeneity in humans?: III. Luteinizing hormone heterogeneity: a medical physiologist's perspective Hum. Reprod., June 1, 2001; 16(6): 1058 - 1064. [Abstract] [Full Text] [PDF]

				C. Castro-Fernández, A. Olivares, D. Söderlund, J. C. López-Alvarenga, E. Zambrano, J. D. Veldhuis, A. Ulloa-Aguirre, and J. P. Méndez A Preponderance of Circulating Basic Isoforms Is Associated with Decreased Plasma Half-Life and Biological to Immunological Ratio of Gonadotropin-Releasing Hormone-Releasable Luteinizing Hormone in Obese Men J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4603 - 4610. [Abstract] [Full Text]

				M. P. Rose, R. E. Gaines Das, and A. H. Balen Definition and Measurement of Follicle Stimulating Hormone Endocr. Rev., February 1, 2000; 21(1): 5 - 22. [Abstract] [Full Text]

				A Preponderance of Basic Luteinizing Hormone (LH) Isoforms Accompanies Inappropriate Hypersecretion of Both Basal and Pulsatile LH in Adolescents with Polycystic Ovarian Syndrome J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4629 - 4636. [Abstract] [Full Text]

				M. D'Antonio, F. Borrelli, A. Datola, R. Bucci, M. Mascia, P. Polletta, D. Piscitelli, and R. Papoian Biological characterization of recombinant human follicle stimulating hormone isoforms Hum. Reprod., May 1, 1999; 14(5): 1160 - 1167. [Abstract] [Full Text] [PDF]

				J. L. Sharpless, J. G. Supko, K. A. Martin, and J. E. Hall Disappearance of Endogenous Luteinizing Hormone Is Prolonged in Postmenopausal Women J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 688 - 694. [Abstract] [Full Text]

				M. Grossmann, B. D. Weintraub, and M. W. Szkudlinski Novel Insights into the Molecular Mechanisms of Human Thyrotropin Action: Structural, Physiological, and Therapeutic Implications for the Glycoprotein Hormone Family Endocr. Rev., August 1, 1997; 18(4): 476 - 501. [Abstract] [Full Text] [PDF]

				M. Grossmann, M. W. Szkudlinski, J. E. Tropea, L. A. Bishop, N. R. Thotakura, P. R. Schofield, and B. D. Weintraub Expression of Human Thyrotropin in Cell Lines with Different Glycosylation Patterns Combined with Mutagenesis of Specific Glycosylation Sites J. Biol. Chem., December 8, 1995; 270(49): 29378 - 29385. [Abstract] [Full Text] [PDF]